High Dose Intensity Chemotherapy for Ovarian Cancer
Author Information
Author(s): J.W. Sweetenham, J.J. McKendrick, D.H. Jones, J.M.A. Whitehouse, C.J. Williams
Primary Institution: CRC Wessex Medical Oncology Unit, Southampton General Hospital
Hypothesis
Can high dose intensity chemotherapy improve outcomes in patients with advanced epithelial ovarian carcinoma?
Conclusion
The study found that while high dose intensity chemotherapy was administered, severe toxicity limited the ability to achieve the planned dose intensity.
Supporting Evidence
- Severe toxicity was experienced by most patients.
- Only one patient received treatment at the planned dose intensity.
- The median received average relative dose intensity was 0.90.
Takeaway
Doctors tried giving a stronger chemotherapy to women with advanced ovarian cancer, but many got too sick to finish the treatment.
Methodology
Nineteen patients received high dose chemotherapy with cisplatin and cyclophosphamide, monitored for toxicity and efficacy.
Potential Biases
Patients were selected from specific gynaecologists, which may introduce selection bias.
Limitations
The study had a small sample size and many patients experienced severe toxicity.
Participant Demographics
Median age was 60 years, with most patients presenting with FIGO stage III disease.
Want to read the original?
Access the complete publication on the publisher's website